Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Further Publications Urology
Related content
Uro-Oncology
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Prostate
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
doi: 10.1002/pros.24880
Uro-Oncology
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis
Prostate
Suzuki K, Hirata J, Okamura Y, Bando Y, Hara T, Terakawa T, Hyodo Y, Chiba K, Teishima J, Miyake H
doi: 10.1002/pros.24889
Benign Prostatic Hyperplasia (BPH)
Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
Prostate
Jirásko M, Viták R, Pecen L, Pinkeová A, Tkáč J, Bertók T, Bergman N, Kučera R
doi: 10.1002/pros.24801
Further Publications Urology
Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms
Prostate
Bâcle C, Mazancourt ES, Abid N, Ruffion A, Rouvière O, Colombel M, Fassi-Fehri H
doi: 10.1002/pros.24906
Benign Prostatic Hyperplasia (BPH)
The Prostate Microbiome Is Associated With Prostate Size and PSA Level, Independent of Age, in BPH Patients
Prostate
Sun A, Rodriguez-Alvarez JS, Harper S, Khooblall P, Dang T, De S, Miller AW
doi: 10.1002/pros.24891
COMMENTED
Uro-Oncology
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
Uro-Oncology
Defining Abnormal Prostate Specific Antigen Values for Prostate Cancer Screening in the Spinal Cord Injury Population
J Urol
Fogg RW, Krzastek SC, Vissichelli N, Defor E, Sabo R, Ghatas M, Sima A, Swavely N, Grob BM, Carter W, Goetz L, Klausner AP
doi: 10.1097/JU.0000000000004644
COMMENTED
Uro-Oncology
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110
Uro-Oncology
History of Vasectomy Is not Associated With Prostate Cancer Progression in Men on Active Surveillance
Prostate
Grutman AJ, Jing Y, Ng DK, Landis PK, Trock BJ, Pavlovich CP
doi: 10.1002/pros.70001